Forsyth Barr says Abano shares should outperform
Abano shares are trading at a discount to both the New Zealand market and its Australian peers.
Hot Topic
Summer features
Forsyth Barr analyst Chelsea Leadbetter has resumed coverage of Abano Healthcare following the failure of the recent takeover attempt and says the shares should outperform.
Abano’s largest shareholder, Healthcare Partners, had wanted to take its stake from 19% to just above 50% but its $10 per
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
Jenny Ruth
Mon, 27 Mar 2017
Mon, 27 Mar 2017
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Forsyth Barr says Abano shares should outperform
65883